The development of CpG island methylation biomarkers using restriction landmark genomic scanning.
The development of CpG island methylation biomarkers using restriction landmark genomic scanning.
复制标题
使用限制性标志基因组扫描开发 CpG 岛甲基化生物标志物。
DOI：
10.1111/j.1749-6632.2003.tb05966.x
复制
发表时间：
2003
影响因子：
5.2
通讯作者：
Plass,Christoph
中科院分区：
文献类型：
--
作者：
Smiraglia,DominicJ;Plass,Christoph
摘要：CpG岛高甲基化是癌症中常见的现象。由于这是 DNA 的一种稳定的分子改变，可以很容易地从极少量的量中检测到，因此 DNA 甲基化是用作分子生物标志物的有吸引力的候选者。最近的研究利用已知为癌症遗传破坏目标的基因的 DNA 甲基化作为癌症早期检测、恶性肿瘤分类、药物治疗反应以及预测结果的标记物。由于目前使用的许多甲基化靶标在各种癌症类型中以相当低的频率甲基化，即使该基因可能经常被其他机制破坏，因此开发在所研究的癌症中以高频率甲基化的额外标记物将是有用的。限制性标志基因组扫描已用于识别多种恶性肿瘤中常见的甲基化靶点。这些标记物可以是癌症类型特异性的或非特异性的，可能被证明是用于诊断或预后目的或用于干预策略的中点分析的有效生物标记物。
Abstract:CpG island hypermethylation is a common occurrence in cancer. Because this is a stable molecular alteration of the DNA, which can be detected easily from very small amounts, DNA methylation is an attractive candidate to use as a molecular biomarker. Recent studies have used DNA methylation of genes known to be targets of genetic disruption in cancer as biomarkers for early detection of cancer, classification of malignancies, response to drug treatment, and as markers predictive of outcome. Since many of the currently used targets of methylation are methylated at rather low frequencies in various cancer types even though the gene may be frequently disrupted by other mechanisms, it would be useful to develop additional markers that are methylated at high frequency in the cancer being studied. Restriction landmark genomic scanning has been used for the identification of frequent targets of methylation in multiple malignancies. These markers, which can be either cancer type‐specific or nonspecific, may prove to be effective biomarkers for diagnostic or prognostic purposes, or for midpoint analysis of intervention strategies.